Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2002 Feb;40(2):351–358. doi: 10.1128/JCM.40.2.351-358.2002

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2002, American Society for Microbiology

PMC Copyright notice

FIG. 3. — EBV loads in patients developing PTLD after SCT. All patients received acyclovir (ACV) prophylaxis until day 30 after SCT. (A) Patient 1 developed high-grade B-cell non-Hodgkin's lymphoma during ganciclovir (GCV) and foscarnet (FC) treatment and received no further PTLD treatment. (B) Patient 3 developed diffuse large-cell B-cell non-Hodgkin's lymphoma during ganciclovir and foscarnet treatment; PTLD regressed after two donor lymphocyte infusions (DLI; solid arrows). (C) Patient 4 developed high-grade B-cell non-Hodgkin's lymphoma during antiviral treatment and received no further PTLD treatment. (D) Patient 6 developed high-grade B-cell non-Hodgkin's lymphoma during foscarnet, ganciclovir, and cidofovir treatment and additionally received donor lymphocyte infusions (solid arrow) and anti-CD20 antibody (Rituximab; dotted arrow). (E) Patient 7 received only acyclovir prophylaxis. (F) Patient 8 developed PTLD after a second transplantation due to primary graft failure. Acyclovir prophylaxis was extended until day 30 after the second transplantation. The patient received anti-CD20 antibody (Rituximab; dotted arrow).